Single dose of inhaled procaterol has a prolonged effect on exercise performance of patients with COPD

Abstract

The aim of this study was to examine the prolonged effect of procaterol, a short-acting bronchodilator, on lung function and exercise performance in patients with moderate to severe COPD. A randomized crossover trial was conducted. We recruited 19 patients with COPD aged 71.6±5.5 years. Patients were randomly assigned to receive either 20 μg inhaled procaterol followed by no-treatment or no-treatment followed by 20 μg inhaled procaterol separated by a washout period of 3±2 days. Lung function and exercise performance, using the incremental shuttle walking test (ISWT), were measured at baseline and 4 hours after receiving each treatment. Baseline forced expiratory volume in 1 second (FEV₁) was 38.5%±17% predicted. There were no significant changes in FEV₁ following inhaled procaterol. However, walking distance increased by 294±113 meters at baseline to 331±119 meters after inhaled procaterol (p<0.001). These findings support the beneficial effects of inhaled procaterol on exercise performance in the absence of any change in FEV₁ when measured at 4 hours following inhalation in subjects with moderate to severe COPD. The inhaled procaterol may be useful for enhancing the effects of exercise training in patients with COPD.

Notes

This article is not subject to United States copyright laws.